Raloxifene Use for The Heart
Status and phase
Completed
Phase 3
Conditions
Breast Neoplasms
Cardiovascular Diseases
Treatments
Drug: placebo
Drug: raloxifene
Details and patient eligibility
About
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Sex
Female
Ages
55+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Postmenopausal women with established coronary heart disease or at risk for a major coronary event.
Exclusion criteria
- Postmenopausal symptoms that required estrogen replacement therapy.
- Suspected or known history of breast or endometrial carcinoma.
- Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.
- New York Heart Association classes III or IV heart failure.
Trial design
Primary purpose
Prevention
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems